Office Number: 203-230-8596
CaroGen Corporation is an emerging vaccine company employing a virus-like vesicle (VLV) platform technology developed at Yale University School of Medicine and exclusively licensed for the development and commercialization of vaccines worldwide.
Our vision is to create new, potentially transformative and first-in-class nanoparticle therapeutic vaccines designed to engage the body’s immune system to both recognize and fight off infectious diseases and cancer. The company is developing a portfolio of vaccine candidates with a lead vaccine program in chronic hepatitis B viral infection (CHB). Worldwide, approximately 240 million people live with CHB and 600,000 die each year from HBV-associated liver disease and cancer.
The hepatitis B program has completed initial proof-of-concept testing in animals and is undergoing optimization for selection of a clinical candidate. We are engaged in discussions and research with academic partners on additional targets and models to assess the efficacy of VLV vaccines against these targets to expand the product pipeline.
CaroGen Announces Publication of HBV Vaccine Preclinical Research
Hamden CT - August 17, 2015 - CaroGen Corporation, an emerging vaccine company, today announced the electronic publication of a research article entitled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection,” which appeared in the August online issue of the Journal of Virology.
CaroGen Fostering Vaccine Development Collaborations with Yale & UConn and Establishing Laboratory
Farmington CT – January 5, 2015 – CaroGen Corporation today announced that it has chosen UConn’s Technology Incubation Program (TIP) in Farmington to establish a laboratory footprint. This expansion will allow CaroGen to more aggressively pursue the advancement of its proprietary virus-like vesicle (VLV) vaccine technology, development of its HBV vaccine program and evaluation of other potential candidate infectious disease vaccines.
CaroGen Receives $500,000 Investment from Connecticut Bioscience Innovation Fund (CBIF)
Hamden CT – December 10, 2014 – CaroGen has been awarded $500,000 from the CBIF to support the continued development of CaroGen's therapeutic Hepatitis B Virus (HBV) vaccine.
CaroGen Wins Entrepreneur Innovation Award from CTNext
Hamden CT – April 3, 2014 – CaroGen was awarded a $10,000 grant by CTNext, a component of Connecticut’s innovation ecosystem to support the success of companies and entrepreneurs, to further support development of its therapeutic vaccine for chronic Hepatitis B (CHB) viral infection.